Galvus Won’t Proceed In U.S. Without More FDA Clarity On Prospects, Novartis Says
DPP-4 inhibitor’s NDA is on hold in U.S. while firm pursues European launch; Novartis balks at FDA request for large safety study.
DPP-4 inhibitor’s NDA is on hold in U.S. while firm pursues European launch; Novartis balks at FDA request for large safety study.